Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
The Korean Journal of Gastroenterology ; : 148-153, 2014.
Article Dans Coréen | WPRIM | ID: wpr-74444

Résumé

Chronic constipation is a very common clinical problem with its prevalence of up to 14% in the general population. It is not a life-threatening disease, but since patient's satisfaction to the treatment is known to be as low as 50%, chronic constipation still remains a clinically challenging problem. Fortunately, many new treatments have been introduced or are to be introduced in the near future. This article will review the basic concepts and the results of recent studies on the new treatments for chronic constipation.


Sujets)
Humains , Agonistes de canaux chlorure/usage thérapeutique , Maladie chronique , Constipation/traitement médicamenteux , Laxatifs/usage thérapeutique , Polyéthylène glycols/usage thérapeutique , Prévalence , Probiotiques/usage thérapeutique , Agonistes des récepteurs 5-HT4 de la sérotonine/usage thérapeutique
2.
The Korean Journal of Gastroenterology ; : 82-99, 2011.
Article Dans Coréen | WPRIM | ID: wpr-11780

Résumé

Traditional symptom-based therapies of irritable bowel syndrome (IBS) are directed at the relief of individual IBS symptoms, but they are often of limited efficacy in addressing the entire symptom complex. Combinations of drugs to target bothersome symptoms are suggested as the first-line pharmacologic treatment. Increasing knowledge of the pathophysiology and molecular mechanisms of IBS has resulted in the development of several new therapeutic approaches. Thirteen consensus statements for the treatment of IBS were developed using the modified Delphi approach. Exclusion diets have modest efficacy in improving symptoms in some IBS patients. Symptom-based therapies with dietary fiber, bulking agents, laxatives, antispasmodics and laxatives are effective in the improvement of some individual symptoms, e.g. dietary fiber and bulking agents for constipation, laxatives for constipation, antispasmodics for abdominal pain and discomfort, antidiarrheals for diarrhea. 5HT3 receptor antagonists and 5HT4 receptor agonists are effective in the relief of global IBS symptoms and individual symptoms such as abdominal pain and abnormal bowel habits. A short term course of nonabsorbable antibiotics may improve global IBS symptoms, particularly in patients with diarrhea- predominant IBS. Some probiotics appear to have the potential benefit in improving global IBS symptoms. Selective C-2 chloride channel activator is more effective than placebo at relieving global IBS symptoms in patients with constipation-predominant IBS. Both tricyclic antidepressants and selective serotonin reuptake inhibitors are equally effective in relieving global IBS symptoms, and have some benefits in treating abdominal pain. Certain types of psychologic therapy may be effective in improving global symptoms in some IBS patients. Further studies are strongly needed to develop better treatment strategies for Korean patients with IBS.


Sujets)
Humains , Anti-infectieux/usage thérapeutique , Antidépresseurs/usage thérapeutique , Antidiarrhéiques/usage thérapeutique , Fibre alimentaire/usage thérapeutique , Syndrome du côlon irritable/thérapie , Laxatifs/usage thérapeutique , Parasympatholytiques/usage thérapeutique , Probiotiques/usage thérapeutique , Agonistes des récepteurs 5-HT4 de la sérotonine/usage thérapeutique , Antisérotonines/usage thérapeutique
SÉLECTION CITATIONS
Détails de la recherche